DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Rheumatoid factor, anti-CCP and ANA testing

Essential points for quick revision.

!
Escalate

Autoantibody testing must not delay assessment of a septic joint, rapidly progressive renal or pulmonary disease, threatened vision, severe cytopenia, myocarditis or neurological deficit. Urinalysis, organ function, imaging, cultures and urgent specialist care may be more consequential than the eventual antibody result.

Synopsis

Request and interpret RF, anti-CCP and ANA only after defining a compatible clinical phenotype, using likelihood, titre, pattern and confirmatory tests without diagnosing autoimmune disease from an isolated antibody.

  • RF is usually an IgM autoantibody directed against the Fc portion of IgG; it occurs in rheumatoid arthritis but also with age, chronic infection, smoking, other autoimmune disease and in some healthy people.
  • Anti-CCP antibodies are more specific for rheumatoid arthritis and carry prognostic information, but a negative result does not exclude seronegative disease.
  • Offer RF when clinical examination confirms synovitis and consider anti-CCP if RF is negative; never delay rheumatology referral while waiting for either result.

Key red flags

Organ-threatening autoimmune signal

Proteinuria, active urine sediment, haemoptysis, hypoxia, myocarditis, severe cytopenia or neurological dysfunction requires urgent organ assessment regardless of antibody status.

Investigation priorities

01
Rheumatoid factorFirst step

Support diagnosis and prognosis when rheumatoid arthritis is suspected from persistent synovitis.

Management branches

Persistent synovitisRefer first and use serology as support

Examination confirms persistent joint swelling compatible with rheumatoid arthritis.

  1. Request RF and consider anti-CCP with baseline FBC, renal and liver tests, while documenting joint distribution, duration and function.
  2. Send rheumatology referral immediately rather than waiting for the results, because negative serology and normal markers do not exclude disease.
Open full textbook Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom